RSV vaccine manufacturers vie for market share in second year of vaccinations
Pfizer, GSK and Moderna’s competition to supply new respiratory syncytial virus (RSV) vaccines is on Wall Street’s watch list as the companies will report their earnings later this week.
BELIEBTE BEITRÄGE
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
Mission: Impossible 8 title revealed
November 13, 2024
LIVEÜBERTRAGUNG